These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17657174)

  • 21. Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.
    Aguiar Bujanda D; Cabrera Suárez MA; Bohn Sarmiento U; Quintero Pérez S; Aguiar Morales J
    Clin Transl Oncol; 2006 Dec; 8(12):919-21. PubMed ID: 17169767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C; Estilo C
    Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonate-induced osteonecrosis of the jaws: a case report and literature review.
    Tsai WS; Haghighi K; Placa SJ
    Gen Dent; 2006; 54(3):215-9; quiz 220-2. PubMed ID: 16776417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonate-related osteonecrosis of the jaws--a case report.
    Kamoh AK; Ogle O
    Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
    Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
    Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid.
    Cohen PR
    Dermatol Online J; 2015 Aug; 21(8):. PubMed ID: 26437156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
    Vieillard MH; Maes JM; Penel G; Facon T; Magro L; Bonneterre J; Cortet B
    Joint Bone Spine; 2008 Jan; 75(1):34-40. PubMed ID: 17981488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.
    Fusco V; Loidoris A; Colella G; Vescovi P; Campisi G
    Breast; 2010 Oct; 19(5):432-3; author reply 433-4. PubMed ID: 20363135
    [No Abstract]   [Full Text] [Related]  

  • 31. Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: Radiologic aspects.
    Wasserzug O; Kaffe I; Lazarovici TS; Weissman T; Yahalom R; Fliss DM; Yarom N
    Am J Rhinol Allergy; 2017 Jan; 31(1):36-39. PubMed ID: 28234151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
    Grant BT; Amenedo C; Freeman K; Kraut RA
    J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
    Dimitrakopoulos I; Magopoulos C; Karakasis D
    Int J Oral Maxillofac Surg; 2006 Jul; 35(7):588-93. PubMed ID: 16687238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
    Olson KB; Hellie CM; Pienta KJ
    Urology; 2005 Sep; 66(3):658. PubMed ID: 16140106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spontaneous bisphosphonate-related osteonecrosis of the left hemi-mandible: similarities with phossy jaw.
    Campisi G; Compilato D; Angelo I; Lo Muzio L; Colella G
    Indian J Dent Res; 2012; 23(5):683-5. PubMed ID: 23422621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of bisphosphonate-related osteonecrosis of the jaw in a patient who had received intravenous bisphosphonates].
    Ishikawa T
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):225-7. PubMed ID: 24743202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: a word of caution for oral surgeons and oncologists.
    Chaturvedi P; Pai PS; Chaukar DA; Gupta S; D'cruz AK
    Eur J Surg Oncol; 2010 Jun; 36(6):541-5. PubMed ID: 20071132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?
    Ardine M; Generali D; Donadio M; Bonardi S; Scoletta M; Vandone AM; Mozzati M; Bertetto O; Bottini A; Dogliotti L; Berruti A
    Ann Oncol; 2006 Aug; 17(8):1336-7. PubMed ID: 16524968
    [No Abstract]   [Full Text] [Related]  

  • 40. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.